EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Home‐Monitoring of Patients With Inflammatory Bowel Disease on Subcutaneous Vedolizumab—A 2‐Year Observational Study

Marwah Al‐Sheikh, Zarah Thomsen, Mette Bennedsen, Gasper Letnar, Petra Weimers, Dorit Vedel Ankersen, Charlotte Teglgaard Peters‐Lehm, Johan Burisch, Pia Munkholm

JCC Plus · 2026-07 · 1 (4)

DOI: 10.1002/jcc5.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCC Plus, online erschienen am 13.07.2026. Verfasst von Marwah Al‐Sheikh und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combined with home‐monitoring, subcutaneous vedolizumab has the potential to promote effective and individualized management in inflammatory bowel diseases (IBDs), as it enables self‐administration and optimizes the use of medical resources. Our study aims to evaluate the feasibility of home‐monitoring based on patient‐reported outcomes (PROs) and fecal calprotectin in patients with IBD treated with subcutaneous vedolizumab.

Methods

This was an observational study of 43 IBD patients diagnosed with Ulcerative colitis (UC) or Crohn's Disease (CD) at North Zealand Hospital in Denmark. Patients were switched from intravenous to subcutaneous vedolizumab from 2020 to 2022 and followed for 2 years via home‐monitoring app; Constant Care (CC). Data retrieved from https://ibd.constant‐care.com/ including Simple Clinical Colitis Activity Index for UC and Harvey–Bradshaw Index for CD, medicine adherence score, quality of life, and fecal calprotectin (using a home testing kit, CalproSmart). Data, including patient descriptions, drug frequency in weeks, IBD‐related hospital admissions, surgeries, and death, were obtained from patient journals (EPIC system).

Results

After the exclusion of two patients, 41 patients, CD ( n = 21) and UC ( n = 20) were switched from intravenous to subcutaneous vedolizumab and followed with CC, with high compliance rates to telemonitoring at year 2 (CD 100%, UC 90%). Treatment was evaluated at baseline, after 1 year, and 2 years. At year 2, 18 patients (43.9%) maintained remission with tendency to shortened treatment interval, of which 6 patients stopped treatment due to remission. Twenty patients (48.8%) discontinued, of which 11 patients (55%) due to adverse events.

Conclusion

Home monitoring has the potential to transform IBD care by delivering real time, long‐term data on patient‐reported outcomes and provides insight into patient‐centered IBD care.

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Al‐Sheikh, M., Thomsen, Z., Bennedsen, M., Letnar, G., Weimers, P., Ankersen, D. V., Peters‐Lehm, C. T., Burisch, J., & Munkholm, P. (2026). Home‐Monitoring of Patients With Inflammatory Bowel Disease on Subcutaneous Vedolizumab—A 2‐Year Observational Study. JCC Plus, 1(4). https://doi.org/10.1002/jcc5.70057

Vancouver

Al‐Sheikh M, Thomsen Z, Bennedsen M, Letnar G, Weimers P, Ankersen DV, et al. Home‐Monitoring of Patients With Inflammatory Bowel Disease on Subcutaneous Vedolizumab—A 2‐Year Observational Study. JCC Plus. 2026;1(4). doi:10.1002/jcc5.70057

BibTeX
@article{AlSheikh2026,
  author = {Al‐Sheikh, Marwah and Thomsen, Zarah and Bennedsen, Mette and Letnar, Gasper and Weimers, Petra and Ankersen, Dorit Vedel and Peters‐Lehm, Charlotte Teglgaard and Burisch, Johan and Munkholm, Pia},
  title = {Home‐Monitoring of Patients With Inflammatory Bowel Disease on Subcutaneous Vedolizumab—A 2‐Year Observational Study},
  journal = {JCC Plus},
  year = {2026},
  volume = {1},
  number = {4},
  doi = {10.1002/jcc5.70057}
}
Kostenlos starten →